| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
GeneDx Holdings (NASDAQ:WGS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $100.0, a high estimate of $115.00, and a low estimate of $80.00. This current average reflects an increase of 20.48% from the previous average price target of $83.00.
A comprehensive examination of how financial experts perceive GeneDx Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brandon Couillard | Wells Fargo | Raises | Equal-Weight | $95.00 | $78.00 |
| David Westenberg | Piper Sandler | Announces | Overweight | $110.00 | - |
| Subbu Nambi | Guggenheim | Raises | Buy | $115.00 | $88.00 |
| Tycho Peterson | Jefferies | Announces | Buy | $80.00 | - |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of GeneDx Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on GeneDx Holdings analyst ratings.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: GeneDx Holdings's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 39.56%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: GeneDx Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): GeneDx Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): GeneDx Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.45, GeneDx Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: WGS
